The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Rhythm Pharmaceuticals 14-Day RSI Related Terms
MEX:RYTM vs MIRM, SYRE, PTGX: 14-Day RSI Comparison
For the Biotechnology subindustry, Rhythm Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (MEX:RYTM) has a 14-Day RSI of 41.65 as of Jul. 07, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Rhythm Pharmaceuticals and its competitors. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #1336 out of 1418 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Rhythm Pharmaceuticals' 14-Day RSI too high?
Rhythm Pharmaceuticals' current 14-Day RSI is 41.65. The Biotechnology industry median 14-Day RSI is 51.24. Rhythm Pharmaceuticals' value of 41.65 is 18.7% below this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #1336 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rhythm Pharmaceuticals has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' 14-Day RSI compare to MIRM and SYRE?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #1336 out of 1418 companies for 14-Day RSI. This places Rhythm Pharmaceuticals in the lower half of its industry. The industry median 14-Day RSI is 51.24. Rhythm Pharmaceuticals' value of 41.65 is 18.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 51.24, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current 14-Day RSI of 41.65 is 18.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Rhythm Pharmaceuticals and its competitors. For the Biotechnology industry, the median 14-Day RSI is 51.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current 14-Day RSI is 41.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current 14-Day RSI of 41.65. The stock's GF Value™ is MXN1,817.22, compared to a current price of MXN1,866.76 — trading 2.7% above its estimated fair value. The current 14-Day RSI is 41.65 and 18.7% below the Biotechnology industry median of 51.24. Rhythm Pharmaceuticals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current 14-Day RSI is 41.65 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,866.76 is trading 2.7% above its estimated GF Value™ of MXN1,817.22.
Key valuation signals for MEX:RYTM:
14-Day RSI: 41.65
GF Value™: MXN1,817.22 vs. price of MXN1,866.76 (2.7% above fair value)
Industry Position: 18.7% below the Biotechnology median (#1336 of 1418)
No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
55GF Score
Get the complete analysis for MEX:RYTM
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RYTM has been successfully added to your 